Brought to you by 
Monogram Biosciences, Pfizer collaborate on HIV assay
May 2006
Executive Summary
Building on a 2002 partnership in HIV, Monogram Biosciences and Pfizer have entered a new three-year deal to collaborate on the development of Monogram's co-receptor tropism assay, which is now being used in clinical trials for HIV/AIDS indications of Pfizer's Maraviroc, a Phase III CCR5-antagonist compound.
Deal Industry
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R+D and Marketing-Licensing
- Includes Equity
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Monogram Biosciences, Pfizer collaborate on HIV assay
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice